147 related articles for article (PubMed ID: 24252676)
1. [A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer].
Liu WQ; Ye JM; Xu L; Liu Q; Zhao JX; Duan XN; Liu YH
Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):706-9. PubMed ID: 24252676
[TBL] [Abstract][Full Text] [Related]
2. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
3. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
5. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
6. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.
Bufi E; Belli P; Di Matteo M; Terribile D; Franceschini G; Nardone L; Petrone G; Bonomo L
Eur J Radiol; 2014 Sep; 83(9):1631-8. PubMed ID: 24938669
[TBL] [Abstract][Full Text] [Related]
7. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
8. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Kim SI; Sohn J; Koo JS; Park SH; Park HS; Park BW
Oncology; 2010; 79(5-6):324-30. PubMed ID: 21430399
[TBL] [Abstract][Full Text] [Related]
9. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
[TBL] [Abstract][Full Text] [Related]
11. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
12. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pathological response to neoadjuvant chemotherapy in breast cancer patients by imaging.
Kaise H; Shimizu F; Akazawa K; Hasegawa Y; Horiguchi J; Miura D; Kohno N; Ishikawa T
J Surg Res; 2018 May; 225():175-180. PubMed ID: 29605029
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
15. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
16. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
Martincich L; Montemurro F; Cirillo S; Marra V; De Rosa G; Ponzone R; Aglietta M; Regge D
Radiol Med; 2003; 106(1-2):51-8. PubMed ID: 12951551
[TBL] [Abstract][Full Text] [Related]
17. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
18. MRI and conservative treatment of locally advanced breast cancer.
Julius T; Kemp SE; Kneeshaw PJ; Chaturvedi A; Drew PJ; Turnbull LW
Eur J Surg Oncol; 2005 Dec; 31(10):1129-34. PubMed ID: 15905068
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Tumor Response After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation Between Dynamic Contrast-enhanced Magnetic Resonance Imaging and Pathologic Tumor Cellularity.
Choi WJ; Kim WK; Shin HJ; Cha JH; Chae EY; Kim HH
Clin Breast Cancer; 2018 Feb; 18(1):e115-e121. PubMed ID: 28890184
[TBL] [Abstract][Full Text] [Related]
20. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
